title: Establishment of a myeloid cell line, YM711, characterized by retinoid resistance.
abstract: A myeloid cell line (YM711) was established by transfecting exogenous PML/RARalpha cDNA into peripheral blood stem cells. The cells were positive for CD33, CD34, CD38, CD13, CD14, and CD11b. Cytochemical examination revealed YM711 cells to be positive for peroxidase, alpha-naphtyl butyrate esterase, and acid phosphatase as well. Karyotypic analysis showed them to be nearly tetraploid (92 XXYY). Reverse-transcription polymerase chain reaction showed that, although PML/RARalpha mRNA was detected in YM711, these cells could not be differentiated by all-trans retinoic acid (ATRA). We therefore designated the YM711 cell line as being ATRA resistant. Because YM711 expressed multi drug resistance 1 (MDR-1) mRNA and p-glycoprotein cell surface protein, we assessed whether verapamil and ATRA would induce the differentiation of YM711 cells; they did not. An increased expression of cellular retinoic acid-binding protein (CRABP)-II was also detected on YM711 cells compared with that of HL-60. These results suggest that high level of expression of CRABP-II may contribute to be the mechanism of ATRA resistance. This cell line may be useful in evaluating the mechanism of resistance to retinoid.
authors.affiliation: Third Department of Internal Medicine, Kinki University School of Medicine, Osaka, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Sumimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Maeda
authors.forename: Y
authors.initials: Y
authors.lastname: Naiki
authors.forename: H
authors.initials: H
authors.lastname: Sono
authors.forename: J I
authors.initials: JI
authors.lastname: Miyatake
authors.forename: M
authors.initials: M
authors.lastname: Sakaguchi
authors.forename: M
authors.initials: M
authors.lastname: Matsuda
authors.forename: A
authors.initials: A
authors.lastname: Kanamaru
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics; D002461:Cell Line, Transformed / Q000166:cytology*; D018076:DNA, Complementary; D019008:Drug Resistance, Neoplasm; D005434:Flow Cytometry; D019450:Genes, MDR / Q000235:genetics; D006801:Humans; D016130:Immunophenotyping; D023461:Myeloid Progenitor Cells / Q000166:cytology*; D009363:Neoplasm Proteins / Q000235:genetics; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D012333:RNA, Messenger / Q000378:metabolism; D018168:Receptors, Retinoic Acid / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection; D014212:Tretinoin; D014407:Tumor Cells, Cultured
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D018076:DNA, Complementary; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; D012333:RNA, Messenger; D018168:Receptors, Retinoic Acid; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; C082928:retinoic acid binding protein II, cellular; D014212:Tretinoin